Advertisement

Breast Cancer Research and Treatment

, Volume 97, Issue 2, pp 223–224 | Cite as

Tamoxifen induced-non-alcoholic steatohepatitis (NASH): Has the time come for the oncologist to be diabetologist

  • M.H. Ahmed
  • K.A. Osman
Letter to the editor

Keywords

Tamoxifen NASH Exemestane Estrogen Receptor Positive Breast Cancer Southampton General Hospital 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, Persico M, Colombo A, Monasterolo F, Casadei-Giunchi D, Desiderio F, Stroffolini T, Decensi A, Veronesi U: Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 330(7497): 932, 2005Google Scholar
  2. 2.
    Ahmed MH, Byrne CD, 2005 non-alcoholic steatohepatitis In: Byrne CD, Wild S, (eds) Metabolic Syndrome England Wiley & Sons Ltd pp. 279–303CrossRefGoogle Scholar
  3. 3.
    Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P, The natural history of non-alcoholic fatty liver disease: a population-based cohort study Gastroenterology2005; 129:113–121PubMedCrossRefGoogle Scholar
  4. 4.
    Ahmed MH, Invasive and non-invasive investigations for non-alcoholic steatohepatitis: the benefit of histology Scand J Gastroenterol 2005 40(10):1260PubMedCrossRefGoogle Scholar
  5. 5.
    Murata Y, Ogawa Y, Saibara T, Nishioka A, Takeuchi N, Kariya S, Onishi S, Yoshida S, Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis Oncol Rep2003; 10:97–100PubMedGoogle Scholar
  6. 6.
    Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T, LIDO Study Group. Sampling variability of liver biopsy in non-alcoholic fatty liver disease Gastroenterology 2005; 128:1898–1906PubMedCrossRefGoogle Scholar
  7. 7.
    Nemoto Y, Toda K, Ono M, et al. Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice J Clin Invest 2000; 105:1819–1825PubMedCrossRefGoogle Scholar
  8. 8.
    Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, Lappas H, Gogas H, The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek Sub-study Breast Cancer Res Treat 2005; 93:61–66PubMedCrossRefGoogle Scholar
  9. 9.
    Wild S, Roglic G, Green A, Sicree R, King H, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 2004 27:1047–1053PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  1. 1.Chemical Pathology DepartmentSouthampton General HospitalSouthamptonUK
  2. 2.Department of SurgeryQueen’s HospitalStaffordshireUK
  3. 3.Chemical Pathology DepartmentSouthampton General HospitalSouthampton UK

Personalised recommendations